AstraZeneca shares fell 1.9% after a US FDA panel voted against recommending its experimental breast cancer drug, citing study design concerns | Collector
Reuters Business
AstraZeneca shares fell 1.9% after a US FDA panel voted against recommending its experimental breast cancer drug, citing study design concerns
AstraZeneca shares fell 1.9% after a US FDA panel voted against recommending its experimental breast cancer drug, citing study design concerns
Reuters Business